orexigen therapeutics inc (OREX) Key Developments
Orexigen Therapeutics Collects $22 Million in Contrave-Linked Payments
Sep 24 15
Orexigen Therapeutics Inc. had received a combined USD 22 million (EUR 19.6 million) in payments from its US and Korean partners for weight management drug Contrave. The amount came from two payments, one of them being a USD 15 million consideration from US partner Takeda Pharmaceuticals. This was the first of three potential anniversary milestone payments of equal size. The other two are expected in the fourth quarters of 2016 and 2017. Orexigen also received USD 7 million by way of an upfront payment from Seoul-based Kwang Dong Pharmaceutical Company Ltd.
Orexigen Therapeutics Eyes Acquisitions
Sep 10 15
Orexigen Therapeutics, Inc. (NasdaqGS:OREX) is looking for acquisitions. The company plans to pursue acquisitions of a diversified portfolio of commercial assets in order to leverage the potential of commercial capabilities we may build in order to maximize profitability and shareholder value and for general working capital purposes.
Orexigen Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 6 15
Orexigen Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $5,194,000 compared to $857,000 a year ago. Loss from operations was $20,728,000 compared to $22,802,000 a year ago. Net loss was $22,504,000 or $0.18 per basic and diluted share compared to $24,507,000 or $0.21 per basic and diluted share a year ago.
For the six months period, the company reported total revenues of $9,553,000 compared to $1,714,000 a year ago. Loss from operations was $36,195,000 compared to $45,956,000 a year ago. Net loss was $39,737,000 or $0.32 per basic and diluted share compared to $49,405,000 or $0.43 per basic and diluted share a year ago.
Orexigen Therapeutics, Inc. Presents at 10th Annual Wells Fargo Healthcare Conference, Sep-10-2015 02:30 PM
Jul 28 15
Orexigen Therapeutics, Inc. Presents at 10th Annual Wells Fargo Healthcare Conference, Sep-10-2015 02:30 PM. Venue: Hyatt Regency, One Avenue de Lafayette, Boston, MA 02210, United States. Speakers: McDavid Stilwell, Vice President of Corporate Communications and Business Development, Michael A. Narachi, Chief Executive Officer, President and Director.
Orexigen Therapeutics, Inc. to Report Q2, 2015 Results on Aug 06, 2015
Jul 24 15
Orexigen Therapeutics, Inc. announced that they will report Q2, 2015 results at 8:00 AM, US Eastern Standard Time on Aug 06, 2015